Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host Disease

Viatris shares are trading lower despite reporting better-than-expected Q2 financial results, possibly dragged down by wider GAAP net loss, near-term supply risks, and weakness in Emerging Markets.

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.

8-K filing — Viatris Inc (VTRS)

Filed: 2026-08-06 AccNo: 0001792044-26-000037 Size: 874 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.60 by 15 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same